{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:56:03Z","timestamp":1790301363228,"version":"4.1.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamaoncol.2020.2169","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T08:32:10Z","timestamp":1590741130000},"page":"1606","source":"Crossref","is-referenced-by-count":122,"title":["Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma"],"prefix":"10.1001","volume":"6","author":[{"given":"Praful","family":"Ravi","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Mantia","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Su","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sorenson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Elhag","sequence":"additional","affiliation":[{"name":"The University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityam","family":"Rathi","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[{"name":"The University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"McGregor","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"cbr200006r1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.609","article-title":"Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).","author":"Tannir","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"cbr200006r2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"cbr200006r3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"cbr200006r4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013positive, advanced non\u2013small-cell lung cancer in the KEYNOTE-010 study.","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"cbr200006r5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"cbr200006r6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"cbr200006r7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade.","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"cbr200006r8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/tca.v11.1","article-title":"Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.","volume":"11","author":"Fujita","year":"2020","journal-title":"Thorac Cancer"},{"issue":"7","key":"cbr200006r9","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","article-title":"Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies.","volume":"39","author":"Fujita","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"cbr200006r10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-017-0273-y","article-title":"Response to single agent PD-1 inhibitor after progression on previous PD-1\/PD-L1 inhibitors: a case series.","volume":"5","author":"Martini","year":"2017","journal-title":"J Immunother Cancer"},{"key":"cbr200006r11","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394.051","article-title":"Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC).","volume":"30","author":"Grimm","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"cbr200006r12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1200\/JCO.2019.37.7_suppl.669","article-title":"Ipilimumab plus nivolumab (Ipi\/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).","volume":"37","author":"Gul","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"cbr200006r13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"cbr200006r14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2766793\/jamaoncology_ravi_2020_br_200006_1619718233.41715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T14:31:20Z","timestamp":1619706680000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2766793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.2169","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}